TORONTO and CAMBRIDGE, MA, June 20,
2018 /PRNewswire/ - ProMIS Neurosciences Inc. (the "Corporation") (TSX: PMN.TO) (OTCQB: ARFXF) would like to remind
shareholders they have until 9:00 am (Toronto Time) on Monday June 25,
2018 to vote their shares for the upcoming Annual General Meeting of shareholders to be held 9:00
am (Toronto Time) on Wednesday June 27, 2018.
Shareholders are urged to carefully read the information circular in connection with the Meeting. A copy of the information
circular in addition to other meeting materials is available on SEDAR at www.sedar.com and on the Corporation's website at www.promisneurosciences.com/agm/
Management recommends a vote FOR all proposed resolutions.
YOUR VOTE IS IMPORTANT REGARDLESS OF THE NUMBER OF SHARES YOU OWN.
PLEASE VOTE TODAY.
HOW TO VOTE
Due to essence of time, shareholders are encouraged to vote today using the internet, telephone or facsimile.
Registered shareholders may vote by:
-
Internet: www.investorvote.com
- Telephone: 1-866-732-8683
- Attending the meeting in person: Brookfield Place, Suite 4400, 181 Bay St., Toronto
ON
Beneficial shareholders may vote by:
Shareholders who hold shares through a bank or other intermediary will have different voting instructions and
should carefully follow the voting instructions provided to them. In most cases, beneficial shareholders will receive a voting
instruction form as part of the meeting materials. Beneficial shareholders are encouraged to complete, sign and return the voting
instruction form in accordance with the instructions on the form.
In addition, certain beneficial shareholders of the Corporation may be contacted by Laurel Hill Advisory Group, the proxy
solicitation agent, to obtain votes directly over the phone utilizing the Broadridge QuickVote™ service.
Matters to be considered by all shareholders attending the Meeting either in person or by proxy are:
(1) receipt of the annual financial statements and management's discussion and analysis for the Corporation's financial
year ended December 31, 2017;
(2) election of directors;
(3) appointment of the auditor and grant authority to the Board to fix the auditor's remuneration; and
(4) consideration of, and if thought fit, to pass a resolution of the disinterested shareholders of the Corporation to
approve the Corporation's 20% rolling stock option plan for continuation.
Board recommendation
The Board strongly recommends shareholders vote in favor of all matters, and, in particular, in favor of the continuation of
the stock option plan. If the resolution to continue the option plan is not approved, then only the options currently outstanding
pursuant to the option plan will remain effective, no further grants of options may be made pursuant to the plan, and any common
shares reserved for exercise under expiring or cancelled option grants pursuant to the plan will not become available for
re-allocation.
Shareholders Questions
Shareholders who have questions regarding the meeting or require assistance with voting may contact Laurel Hill Advisory
Group, the proxy solicitation agent, by telephone or email as set forth below.
Laurel Hill Advisory Group
By telephone (North American Toll Free) at: 1-877-452-7184
By telephone (Collect outside North America) at: +1-416-304-0211
By email at: assistance@laurelhill.com
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine
therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and
Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques.
The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel
targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision
medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in
Toronto, Ontario, with offices in Cambridge, Massachusetts.
ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol
ARFXF.
For further information please consult the Company's website at: www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts
responsibility for the adequacy or accuracy of this release. This news release contains certain "forward-looking
statements" within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not
historical facts; they are generally, but not always, identified by the words "expects", "plans", "anticipates", believes",
"intends", "estimates", "projects", "aims", "potential", "goal", "objective", "prospective", and similar expressions, or that
events or conditions "will", "would", "may", "can", "could" or "should" occur. Forward-looking statements are based on the
beliefs, estimates and opinions of the Company's management on the date the statements are made and they involve a number of
risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual
results and future events could differ materially from those anticipated in such statements. Except as required by the securities
disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking
statements if management's beliefs, estimates or opinions, or other factors, should change.
View original content with multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-reminds-shareholders-of-june-25th-voting-cut-off-for-upcoming-annual-general-meeting-300669315.html
SOURCE ProMIS Neurosciences Inc.